MONARCH 2: Phase III Study of Abemaciclib + Fulvestrant in HR+/HER2- Advanced Breast Cancer After Progression on Endocrine Therapy

June 2-6, 2017; Chicago, Illinois

Addition of the CDK4/6 inhibitor abemaciclib to fulvestrant reduced the risk of disease progression by 45%, with an acceptable tolerability profile.

Format: Microsoft PowerPoint (.ppt)

File Size: 523 KB

Released: June 7, 2017

Acknowledgements

Supported by educational grants by

AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Cookie Settings